Ampersand Biomedicines Visa Sponsorship USA

INTRODUCTION

Ampersand Biomedicines is a Flagship Pioneering company on a mission to transform patients’ lives with programmed medicines that work precisely where needed, and nowhere else. We’re building a collaborative, mission-driven team that thrives in a fast-paced environment and shares a genuine desire to make a difference. We ACT our values by working with Agility to adapt and deliver impact, leading with Compassion to put people first, and practicing Transparency to build trust through openness, clarity, and integrity. At Ampersand, employees are encouraged to explore breakthrough science, take chances, support one another, and contribute ideas and perspectives openly.

THE ROLE

Ampersand is currently seeking a highly motivated scientist with a background in antibody-oligonucleotide/drug conjugate (AOC/ADC) and protein sciences to contribute to the discovery and development of AND-Body™ Therapeutics. This position will emphasize creating and analyzing new antibody modalities to develop biologic therapies targeted at specific tissues.

Key Responsibilities

- Collaborate with cross-functional teams to develop AOC/ADC biomolecules that enable targeted delivery to tissues of high interest.
- Co-lead AOC/ADC projects to advance therapeutic candidates, working closely with Ampersand stakeholders, advisors, and CRO collaborators.
- Supervise the design and execution of studies, as well as in the interpretation of data for both in vitro and in vivo research.
- Develop a state-of-the-art platform to facilitate biophysical and biochemical analyses of novel antibody modalities.

Required Professional Experience & Qualifications

- Strong technical background in AOCs; direct experience with siRNA design, antibody engineering, bioconjugation chemistry, or oligonucleotide therapeutics is highly preferred.
- PhD in Biochemistry, Chemical Biology, or a related scientific discipline with 2+ years of experience; exceptional candidates with significant experience and without a doctorate will be considered.
- Previous industry experience is advantageous but not required.
- Hands-on experience in chromatography (ÄKTA, SEC, HIC, and IEX) and protein analytics (mass spectrometry, DLS).
- Direct experience with aseptic mammalian cell culture and plasmid transfection.
- Experience managing CROs.
- Excellent written and verbal communication skills, with the ability to clearly interpret data and present results to project teams.

Preferred Professional Experience & Qualifications

- Experience with site-specific, bioorthogonal conjugation technologies (e.g., engineered cysteines, enzymatic conjugation).
- Knowledge of linker chemistry and stability optimization strategies.
- Experience working in a biotech or translational research environment.
- Strong statistical and data analysis skills.

Ampersand Biomedicines is committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

Recruitment & Staffing Agencies: Ampersand Biomedicines does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Ampersand and/or Flagship Pioneering or its employees is strictly prohibited unless contacted directly by Ampersand or Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Ampersand and FSP, and Ampersand/FSP will not owe any referral or other fees with respect thereto.

COMPENSATION

- Salary Range: $100,000.00 - $143,000.00.

Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Ampersand currently offers healthcare coverage, annual incentive program, retirement benefits and a broad range of other benefits. Compensation and benefits information is based on Ampersand’s good faith estimate as of the date of publication and may be modified in the future.